AR063139A1 - Inhibidores de metaloproteasas derivados de heterociclos. composiciones farmaceuticas. - Google Patents

Inhibidores de metaloproteasas derivados de heterociclos. composiciones farmaceuticas.

Info

Publication number
AR063139A1
AR063139A1 ARP070104410A ARP070104410A AR063139A1 AR 063139 A1 AR063139 A1 AR 063139A1 AR P070104410 A ARP070104410 A AR P070104410A AR P070104410 A ARP070104410 A AR P070104410A AR 063139 A1 AR063139 A1 AR 063139A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
heteroaryl
aryl
alkyl
independently selected
Prior art date
Application number
ARP070104410A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR063139A1 publication Critical patent/AR063139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composiciones farmacéuticas que los comprenden, para tratar trastornos aliviados por el antagonismo de metaloproteasas de matriz. Reivindicacion 1: Un compuesto de formula (1): donde el anillo a es un anillo de 6, 7, 8 o 9 miembros seleccionado de heteroarilo y heterociclilo, donde X es O o S. E se selecciona de un carbono sp2, formula 2 y N, donde R5 se selecciona de H, hidroxi, amino, alcoxi, alquiltio, sulfonilo, alquilo C1-10, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo y heterociclilo, y Q es N o un carbono sp2, con la salvedad de que cuando E es un carbono sp2, Q es N; el Anillo b se selecciona de arilo; heteroarilo; y heterociclilo de la formula 3, donde G1 y G2 se seleccionan en forma independiente de N, C, y CH; y D1 y D2 son cada uno 1-3 miembros independientes seleccionados de CH, CH2, N, S y O, con la salvedad de que cuando G1 o G2 es N, D1 y D2 se seleccionan en forma independiente de CH y CH2; R1 se selecciona de halo, nitrilo, hidroxilo, tiol, amino, alcoxi, alquiltio, sulfonilo, alquilo C1-10, alquenilo C2-6, alquinilo C2-6, cicloalquilo, arilo, heteroarilo, heterociclilo, carbonilo y -CHO; R2 es 0-2 miembros independientes seleccionados de halo, nitrilo, hidroxilo, amino, alquilo C1-10, alquenilo C2-6, alquinilo C2-6, alcoxi, alquiltio, sulfonilo, arilo, heteroarilo, heterociclilo, -C(O)R3, -C(O)OR3 y -C(O)NR3R4, donde R3 y R4 se seleccionan en forma independiente de H, alquilo C1-10, arilo, heteroarilo y heterociclilo, o R3 y R4 junto con el N al que están unidos forman un heterociclilo de 3, 4, 5, 6 o 7 miembros; W se selecciona de un enlace covalente, -(CH2)p-O-, -O-(CH2)p-, -S(O)p-, -C(O)-, alquileno C1-3, alquenileno C2-3, alquinileno C2-3, y un anillo alifático de 5-7 miembros que contiene uno o dos nitrogenos, donde p es 0, 1 o 2; Y se selecciona de O, S, S(O), S(O)2, -SO2N(R6)-, -N(R6)SO2-, -N(R6)SO2N(R7)-, -N(R6)CO-, -N(R6)PO(OR8)-, -N(SO2R8)-, -N(COR8)-, -N(POOR8R9)-, -CH(OH)-, formula 4 y 5, donde R6 y R7 se seleccionan en forma independiente de H, alquilo C1-10, alquilsulfonilo, arilsulfonilo, alquilcarbonilo y arilcarbonilo, y R8 y R9 se seleccionan en forma independiente de alquilo C1-6, arilo, heteroarilo y heterociclilo; Z es -CH(R10)- o - CH(R10)CH(R11)-, donde R10 y R11 se seleccionan en forma independiente de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo y heterociclilo; m es 0, 1 o 2; y n es 0 o 1 con la salvedad de que cuando n es O, E no es N e Y no es O; o un isomero optico, enantiomero, diastereomero, racemato, profármaco o sal aceptable para uso farmacéutico de los mismos.
ARP070104410A 2006-10-05 2007-10-04 Inhibidores de metaloproteasas derivados de heterociclos. composiciones farmaceuticas. AR063139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82822606P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
AR063139A1 true AR063139A1 (es) 2008-12-30

Family

ID=39144447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104410A AR063139A1 (es) 2006-10-05 2007-10-04 Inhibidores de metaloproteasas derivados de heterociclos. composiciones farmaceuticas.

Country Status (23)

Country Link
US (2) US7803793B2 (es)
EP (1) EP2089365A1 (es)
JP (1) JP2010505860A (es)
KR (1) KR20090106385A (es)
CN (1) CN101547908A (es)
AR (1) AR063139A1 (es)
AU (1) AU2007307990A1 (es)
BR (1) BRPI0720547A2 (es)
CA (1) CA2665629A1 (es)
CL (1) CL2007002887A1 (es)
CO (1) CO6190553A2 (es)
CR (1) CR10766A (es)
EA (1) EA200970349A1 (es)
IL (1) IL198014A0 (es)
MX (1) MX2009003763A (es)
NI (1) NI200900052A (es)
NO (1) NO20091463L (es)
PE (1) PE20081174A1 (es)
SV (1) SV2009003212A (es)
TW (1) TW200831501A (es)
UY (1) UY30627A1 (es)
WO (1) WO2008045668A1 (es)
ZA (1) ZA200903058B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
ES2909122T3 (es) 2015-11-09 2022-05-05 Forge Therapeutics Inc Compuestos a base de hidroxipiridinona e hidroxipirimidinona para el tratamiento de infecciones bacterianas
EP3374355A4 (en) 2015-11-09 2019-04-17 Forge Therapeutics, Inc. PYRONE COMPOUNDS FOR TREATING BACTERIAL INFECTIONS
EP3621962A4 (en) 2017-05-10 2020-12-09 Forge Therapeutics, Inc. ANTIBACTERIAL COMPOUNDS
US20200095236A1 (en) * 2017-05-10 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
WO2020061375A1 (en) 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
US11731962B2 (en) 2020-03-25 2023-08-22 Blacksmith Medicines, Inc. LpxC inhibitor and methods of making
CN115969980B (zh) * 2022-12-30 2023-10-24 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胃癌的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
JP2001513771A (ja) 1997-02-27 2001-09-04 アメリカン・サイアナミド・カンパニー マトリクス金属プロテイナーゼ阻害薬としてのｎ−ヒドロキシ−２−（アルキル、アリール、またはヘテロアリールスルファニル、スルフィニルまたはスルホニル）−３−置換アルキル、アリールまたはヘテロアリールアミド
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
EP1755586A2 (en) * 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors

Also Published As

Publication number Publication date
NI200900052A (es) 2010-02-01
BRPI0720547A2 (pt) 2014-05-06
US7803793B2 (en) 2010-09-28
CA2665629A1 (en) 2008-04-17
WO2008045668A1 (en) 2008-04-17
SV2009003212A (es) 2010-08-10
EA200970349A1 (ru) 2010-02-26
CR10766A (es) 2009-09-14
US20100279986A1 (en) 2010-11-04
CL2007002887A1 (es) 2008-06-06
US20080103129A1 (en) 2008-05-01
NO20091463L (no) 2009-06-24
UY30627A1 (es) 2008-05-02
TW200831501A (en) 2008-08-01
KR20090106385A (ko) 2009-10-08
CO6190553A2 (es) 2010-08-19
ZA200903058B (en) 2010-07-28
EP2089365A1 (en) 2009-08-19
MX2009003763A (es) 2009-04-22
AU2007307990A1 (en) 2008-04-17
JP2010505860A (ja) 2010-02-25
CN101547908A (zh) 2009-09-30
PE20081174A1 (es) 2008-09-04
IL198014A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
AR063139A1 (es) Inhibidores de metaloproteasas derivados de heterociclos. composiciones farmaceuticas.
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
PE20221010A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
AR094148A1 (es) Dihidropiridopirazinonas inhibidoras de la proteina bet
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR049291A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AR088218A1 (es) Compuestos heterociclicos utiles como inhibidores de pi3k
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR064353A1 (es) Compuestos y composiciones como inhibidores de la actividad del receptor cannabinoide 1. procesos de obtencion.
AR069326A1 (es) Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia.
CO6321170A2 (es) Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos
AR084366A1 (es) N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
AR062508A1 (es) Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio
AR051293A1 (es) Inhibidores bace
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR054287A1 (es) Combinacion de herbicidas y antidotos
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
AR090293A1 (es) Inhibidores de quinasa a base de arileter

Legal Events

Date Code Title Description
FA Abandonment or withdrawal